Clonidine is a central alpha-2 adrenergic agonist sold in the U.S. under 11 brand and generic names, for attention deficit disorder with hyperactivity, diarrhea and dysmenorrhea. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Javadin (application NDA220256). Other clonidine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Initial dosage is 0.1 mg orally twice daily with or without food (morning and bedtime) ( 2.1 ) Titrate in increments of 0.1 mg per day at weekly intervals if necessary until the desired response is achieved. ( 2.1 ) The therapeutic doses most commonly used have ranged from 0.2 mg to 0.6 mg per day, given in divided doses. ( 2.1 ) Maximum recommended daily dose is 2.4 mg. ( 2.1 ) 2.1 Recommended Dosage Dosage should be individualized based on response. The recommended initial dosage is 0.1 mg orally twice daily (morning and bedtime). Dosage can be titrated in increments of 0.1 mg per day at weekly intervals as necessary. Doses should be taken twice a day, with either an equal or higher split dosage being given at bedtime. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day, given in divided doses. Maximum recommended daily dose is 2.4 mg, but doses as high as this have rarely been employed. 2.2 Administration Instructions A calibrated measuring device, such as an oral dosing syringe or oral dosing cup, is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device. Administer JAVADIN (clonidine hydrochloride) oral solution with or without food. [see Clinical Pharmacology ( 12.3 )] JAVADIN may be administered up to 4 hours before surgery and resume as soon as possible…
The following clinically significant adverse reactions are discussed elsewhere in the labeling: Bradycardia, Cardiac Conduction Abnormalities, and Symptomatic Hypotension [see Warnings and Precautions ( 5.1 )] Rebound Hypertension [see Warnings and Precautions ( 5.2 )] Sedation and Somnolence [see Warnings and Precautions ( 5.3 )] The most frequent adverse reactions are dry mouth, drowsiness, dizziness, constipation and sedation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc., at 1-800-461-7449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth (40%), drowsiness (33%); dizziness (16%); constipation and sedation (10%, respectively). The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride tablets, but in many cases patients were receiving concomitant medication and a causal relationship has not been established. Body as a Whole: Fatigue, headache, pallor,…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Solution | Generic | $1 | View → | |
| 2 | 72/100 | Prescription | Suspension | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| MP;657 | 0.1 mg | yellow | round | — |
| 05 | 0.05 mg | yellow | oval | — |
| MP;657 | 0.1 mg | yellow | round | — |
| MP;658 | 0.2 mg | white | round | — |
| MP;659 | 0.3 mg | green | round | — |
| R128 | 0.2 mg | orange |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Mar 19, 2026
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Mar 19, 2026
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals USA, Inc · Mar 19, 2026
R.E.C.K. (Ropivacaine HCl
Presence of Particulate Matter
QuVa Pharma, Inc. · Oct 10, 2025
The elimination half-life of clonidine is about 12 to 16 hours. The half-life gets much longer when the kidneys are not working well — up to about 41 hours in people with severe kidney impairment.
Clonidine Hydrochloride Tablets, USP (DailyMed) ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
JAVADIN is contraindicated in patients with known hypersensitivity to clonidine. [see Adverse Reactions ( 6 )]. • JAVADIN is contraindicated in patients with known hypersensitivity to clonidine ( 4 )
The interactions of JAVADIN with co-administration of other drugs have not been studied. The drug interaction data provided in this section is based on oral immediate-release clonidine formulations. Table 1 displays clinically important drug interactions with JAVADIN. Table 1: Clinically Important Drug Interactions with JAVADIN. Antihypertensive drugs Clinical Implication Concomitant use of antihypertensive drugs with clonidine potentiates the hypotensive effects of clonidine [see Warnings and Precautions ( 5.1 )]. Intervention Monitor blood pressure and heart rate, and adjust dosage of JAVADIN accordingly in patients treated concomitantly with antihypertensives CNS depressants Clinical Implication Concomitant use of CNS depressants with clonidine potentiates the sedating effects [see Warnings and Precautions ( 5.3 )]. Intervention Avoid concomitant use of CNS depressants with JAVADIN. Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions ( 5.1 )]. Intervention Avoid concomitant use of drugs that affect sinus node function or AV node conduction with JAVADIN. Tricyclic antidepressants Clinical Implication Concomitant use of…
| $1 |
| View → |
| 3 | 70/100 | Prescription | Tablet | Generic | $1 | View → |
| 4 | 70/100 | Prescription | Injectable | Generic | $1 | View → |
| 5 | 68/100 | Prescription | Injectable | Generic | $1 | View → |
| 6 | Not yet rated | Prescription | Patch | Generic | $1 | View → |
| 7 | Not yet rated | Prescription | Patch | Generic | $1 | View → |
| 8 | Not yet rated | Prescription | Patch | Generic | $1 | View → |
| 9 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
| 10 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
| round |
| — |
| MP;659 | 0.3 mg | green | round | — |
|---|
| MP;657 | 0.1 mg | yellow | round | — |
|---|